Durvalumab plus monalizumab for non-invasive bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests two immunotherapy drugs (durvalumab and monalizumab) in people with a type of bladder cancer that hasn't spread into the deep muscle layer. The goal is to see if this combination can help control the cancer and prevent it from coming back, possibly avoiding the need for bladder removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-muscle-invasive bladder cancer (NMIBC) that has come back or not gone away after BCG treatment.
- You are not a candidate for bladder removal surgery or you have refused it.
- You have had all visible tumors removed by surgery, or you have only carcinoma in situ (CIS) left.
- You have not been treated before with certain immunotherapy drugs (PD-1/PD-L1 blockers).
- You are willing to provide tissue samples from your previous bladder surgeries for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This study tests an immunotherapy drug (toripalimab) alone or followed by medication placed directly into the bladder (gemcitabine and mitomycin C) for people with high-risk bladder cancer that has not spread into the muscle wall and that has not responded to or couldn't be handled with BCG therapy. The goal is to see which approach works better.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
This early-phase trial tests durvalumab given with an experimental bladder cancer vaccine to help stop or slow high-risk bladder cancer that did not respond to or cannot be treated with BCG. It also evaluates safety and how well the treatment works in this setting.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.